ArticleFrontiers in cardiovascular medicine2026
Improvement in left atrial strain after percutaneous mitral valvuloplasty is an independent prognostic marker in patients with rheumatic mitral stenosis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatic mitral stenosis (MS) leads to left atrial (LA) pressure overload, resulting in progressive atrial remodeling and dysfunction. Percutaneous mitral valvuloplasty (PMV) relieves LA pressure overload and is the primary treatment for severe MS. LA reservoir strain (LASr), assessed by speckle-tracking echocardiography, allows early detection of LA dysfunction, which may improve immediately after the procedure, with potential prognostic implications. In this study, we analyzed the prognostic value of post-procedural improvement in LASr beyond well-established predictors. Methods: Patients with rheumatic MS undergoing PMV were prospectively recruited. All patients underwent a transthoracic echocardiogram before and within 48 h after the procedure. The primary outcome was a composite of cardiac death or need for mitral valve replacement (MVR). The prognostic value of the change in LASr post and pre PMV (ΔLASr) was assessed using a Cox proportional hazards model adjusted for known prognostic factors. Results: In total, 163 patients were included. Overall, patients were aged 46 (IQR 37-54) years, 82.8% were female, median mitral valve area pre PMV was 0.97 (IQR 0.82-1.13) cm Conclusion: Improvement in LASr independently predicted clinical outcomes in patients with rheumatic MS undergoing PMV, with each unit increase in ΔLASr associated with a 7% risk reduction of death or MVR. Assessment of LASr may be a valuable tool for post-procedural risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.